Our data strongly suggest that the shift between tumor suppressive and tumor promoting TGF-β effects involves different regulation of Smad3 dependent transcription, TβRI expression, Smad2 signaling duration, and endogenous TGF-β/Smad7/TβRII levels. The gene discussed is TGFBR2; the disease is neoplasm.